CdcA4 Antibodies

Santa Cruz Biotechnology delivers a wide array of CdcA4 monoclonal antibodies for research in cell cycle regulation and cancer biology. CdcA4 monoclonal antibodies are validated for western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CdcA4, also known as cell division cycle 4, plays a critical role in the regulation of the cell cycle and is involved in the ubiquitin-proteasome pathway, which controls the degradation of cell cycle proteins. CdcA4 dysregulation has been implicated in various cancers, making it a significant target for therapeutic intervention and biomarker discovery. Understanding CdcA4 function is essential for elucidating the mechanisms of tumorigenesis and developing potential cancer treatments. Researchers can explore CdcA4's role in cell cycle checkpoints and DNA damage response pathways. Advanced imaging techniques combined with CdcA4 monoclonal antibodies enable visualization of protein localization and interactions within cellular compartments. Investigation of CdcA4 expression patterns helps identify potential therapeutic targets in cancer research. Santa Cruz Biotechnology monoclonal antibodies for CdcA4 support researchers worldwide in advancing our understanding of cell cycle regulation and cancer biology.